Shah Capital has fired a broadside at the management team of Novavax, seeking a change in leadership at the vaccine company and the appointment of two handpicked directors to the board.
Novavax investor Shah Capital pushes for board shakeup
April 15 (Reuters) - U.S.-based hedge fund Shah Capital on Monday recommended the appointment of two new independent directors to the Novavax (NVAX.O), opens new tab board.
GAITHERSBURG, Md., April 1, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will showcase continued progress on data from its updated COVID-19 vaccine (NVX-CoV2601) and provide an overview of its influenza and COVID-19-Influenza Combination (CIC) vaccine candidates at the World Vaccine Congress 2024 (WVC) in Washington, DC, April 2 to 4, 2024.
Novavax to Participate in TD Cowen's 44th Annual Health Care Conference
Novavax’s COVID-19 Vaccine Available as Additional Dose for Individuals Aged 65
The company's loss per share of $1.44 exceeded analyst expectations of 45 cents per share, CNBC reports, while its fourth-quarter revenues of $291.3 million came short of the analysts' estimate of $322 million. Novavax's stock was trading down by about 23% just before 9 a.m. ET on Wednesday.
Novavax settles dispute with international vaccine group Gavi
Novavax to Host Conference to Discuss Q4 and Full Year 2023 Financial Results
R21/Matrix-M™ Malaria Vaccine Phase 3 Trial Results Published in The Lancet